No Data
Announcement of research paper publication on domestic Phase III trial (SPP2C102 trial) for the purpose of changing the usage of 'Araglio Granule Pack 1.5g' and 'Araglio Oral Agent 1.5g'.
On November 12, 2024, SBI Pharma Co., Ltd., a subsidiary of SBI Holdings Co., Ltd., is conducting research and development of pharmaceuticals using 5-aminolevulinic acid (5-ALA) (*1). The company located in Minato-ku, Tokyo, with President and Executive Officer Yoshitaka Kitao, hereinafter referred to as the 'Company,' conducted a domestic Phase III trial (SPP2C102 trial) aiming to change the usage of 'Aragurio Granule Pack 1.5g' and 'Aragurio Internal Agent 1.5g'.
SBI Holdings, Inc. (SBHGF) Financial Results for the Six-month Period Ended September 30, 2024 Earnings Call Transcript Summary
SBI Holdings Announces Interim Dividend for FY 2025
SBI Holdings Shows Strong Growth in 2024 Interim Results
SBI Holdings: Notice Concerning Dividends from Surplus Funds (Interim Dividend)
SBI Holdings: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)
No Data
No Data